Number of Previous Cesarean Sections on the Results of Angiogenic Factors.

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorSaint Thomas Hospital, Panama

About this trial

Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries. The only cure for THE is termination of pregnancy, which ends up being a decision in which gestational age and maternal risks must be balanced. Angiogenic factors have come to occupy an indispensable place in the arsenal of tools that can be used to separate the patient with a high likelihood of complications from those in whom prolongation of pregnancy could represent an important neonatal benefit.

Although the usefulness of angiogenic factors in these scenarios is known, little is known about the effects that other conditions might have on their serum levels, mainly those that have an effect on trophoblastic invasion, the process that initiates implantation of the pregnancy in the endometrium. The purpose of the present study is to assess the effect that a history of uterine surgery, such as caesarean section, might have on angiogenic factor scores in subjects with no history of a hypertensive disorder of pregnancy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

36 weeks of gestation or more

Singleton pregnancy

Previous cesarean section (case)

Disqualifiers

Vasculitis

Twin pregnancy

Chronic endometritis

Smoking

Trial population

Pregnant woman with a previous cesarean section

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • sFlt-1/PGIF

    Diagnostic test

    Index of sFlt-1/PGIF

Treatment groups

540 Participants
are divided into 2 treatment groups
Group A: Previous Cesarean Section1 intervention
Group B: No Cesarean1 intervention

Trial outcomes

Primary outcomes

1

Index sFlt-1/PIGF

Angiogenic factors, normal value.

Time frame
From the moment of randomization up until delivery. Between 24-48 hours.

Secondary outcomes

1

Progression to preeclampsia

Number of subjects that develop a preeclampsia

Time frame
Up until discharge. On average, 7 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: